Skip to main content

Table 2 Preventive drugs used in studied patients

From: Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study

 

EM (n = 19)

CM (n = 10)

All (n = 29)

Types of preventive drugs

 Lomerizine

14 (73.7)

8 (80.0)

22 (75.9)

 Propranolol

2 (10.5)

1 (10.0)

3 (10.3)

 Valproate

11 (57.9)

7 (70.0)

18 (62.1)

 Amitriptyline

5 (26.3)

2 (20.0)

7 (24.1)

 Topiramate

2 (10.5)

2 (20.0)

4 (13.8)

Number of preventive drug(s) used

 1

9 (47.4)

2 (20.0)

11 (37.9)

 2

6 (31.6)

6 (60.0)

12 (41.4)

 3

3 (15.8)

2 (20.0)

5 (17.2)

 4

1 (5.3)

0 (0.0)

1 (3.4)

 5

0 (0.0)

0 (0.0)

0 (0.0)

 Mean

1.8 ± 0.9

2.0 ± 0.7

1.9 ± 0.8

Use of preventive drug at the first dosage

 No

6 (31.6)

3 (30.0)

9 (31.0)

 Yes

13 (68.4)

7 (70.0)

20 (69.0)

  Discontinued

5 (26.3)

4 (40.0)

9 (31.0)

  Continued

8 (42.1)

3 (30.0)

11 (37.9)

  1. Data are presented as n (%) or mean ± standard deviation
  2. The preventive drugs assessed are lomerizine, propranolol, valproate, amitriptyline, and topiramate
  3. EM episodic migraine, CM chronic migraine